Our results suggest that the use of DEHP-containing medical devices should be regulated to reduce patient DEHP exposure, and that P-glycoprotein inhibitors might improve outcomes for advanced or drug-resistant colon cancer patients. The gene discussed is ABCB1; the disease is malignant colon neoplasm.